04.09.2018 • NewsDede WillamsServierShire

Shire sells Oncology Portfolio to Servier

Shire sells Oncology Portfolio to Servier (c) anyaivanova/Shutterstock
Shire sells Oncology Portfolio to Servier (c) anyaivanova/Shutterstock

Ahead of its acquisition by Japan’s Takeda Pharmaceutical, Ireland-domiciled, London-listed and US-focused Shire has completed the sale of its oncology portfolio with $262 million in annual sales to French drugmaker Servier for $2.4 billion.

The deal, announced in April during Takeda’s grab for Shire but according to the French company planned earlier, will allow privately held Servier to establish a direct commercial presence in the US while boosting its presence in the cancer segment in countries where it is already present.

After Takeda made five bids for Shire, starting in late March of this year, the £46 billion transaction due to complete shortly was approved by both companies’ boards in May and given unconditional clearance by the US Food and Drug Administration (FDA) in July.

With the buy, Servier will pick up two marketed products, Oncaspar, a treatment for acute lymphoblastic leukemia, and gain non-US rights to Onivyde for pancreatic cancer. It will also take on two development collaborations in the immuno-oncology field.

In the US, Servier’s products will be marketed by the drugmaker’s new subsidiary, Servier Pharmaceuticals, based in Boston, Massachusetts. The company to be headed by David K. Lee,  who previously led Shire’s Global Genetic Diseases and Oncology franchises, will have 80 employees, including some transferring from Shire.

Servier said its US arm aims to develop a strong sales presence in the country based on its existing portfolio while at the same time enriching offerings with close-to-market or already marketed innovative products.

With the acquisition, President Olivier Laureau said the French company is “taking another step toward its strategic goal to become a global player in biopharmaceutical.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read